Display options
Cite
Teagarden JR, Daniels N, Sabin JE. A proposed ethical framework for prescription drug benefit allocation policy. J Am Pharm Assoc (Wash). 2003;43(1):69-74doi: 10.1331/10865800360467079.
Teagarden, J. R., Daniels, N., & Sabin, J. E. (2003). A proposed ethical framework for prescription drug benefit allocation policy. Journal of the American Pharmaceutical Association (Washington, D.C. : 1996), 43(1), 69-74. https://doi.org/10.1331/10865800360467079
Teagarden, J Russell, et al. "A proposed ethical framework for prescription drug benefit allocation policy." Journal of the American Pharmaceutical Association (Washington, D.C. : 1996) vol. 43,1 (2003): 69-74. doi: https://doi.org/10.1331/10865800360467079
Teagarden JR, Daniels N, Sabin JE. A proposed ethical framework for prescription drug benefit allocation policy. J Am Pharm Assoc (Wash). 2003 Jan;43(1):69-74. doi: 10.1331/10865800360467079. PMID: 23945807.
Copy Download .nbib Format: NLM
Share it on

J Am Pharm Assoc (Wash). 2003 Jan;43(1):69-74. doi: 10.1331/10865800360467079.

A proposed ethical framework for prescription drug benefit allocation policy.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)

J Russell Teagarden, Norman Daniels, James E Sabin

PMID: 23945807 DOI: 10.1331/10865800360467079

Abstract

OBJECTIVES To presentan ethical framework that could aid prescription drug benefit design and to propose that such a framework could be organized around a benefit allocation hierarchy. SUMMARY Four hierarchical levels of allocation are proposed, as follows: (1) drug categories and subcategories, (2) individual drugs within covered drug categories, (3) specific indications of covered drugs, and (4) special features of drug use, such as quantities covered for specific indications. Rationales for decision making should address the distinct ethical issues apparent at each level. CONCLUSION Ethical issues associated with designing and managing a pharmacy benefit can be identified by using a hierarchical prescription drug allocation scheme. Articulating these issues is an important first step toward arriving at a fully developed framework that will serve to produce rationales acceptable to typical stakeholders in prescription drug benefits.

Publication Types